Kasinvaziv Olmayan Mesane Tümörlerinde Tedavi Protokolü
Özet
Mesane kanseri, dünya çapında erkeklerde yedinci, kadınlarda ise on yedinci en yaygın malignite olarak sıralanmaktadır. Tütün dumanına kümülatif maruziyet, kanser gelişimi için güçlü bir risk ile ilişkilidir. Sigarayı bırakmak mesane kanseri gelişimi riskini azaltabilir. Ortaya çıkan veriler aktif izlemin seçilmiş Kasa invaze olmayan mesane kanserlerinde(KİOMK) hastalarında güvenli ve geçerli bir seçenek olduğunu öne sürse de, bu hala standart bir uygulama olarak kabul görmemiştir. Transüretral rezeksiyon (TUR), mesanenin Ta T1 evre Transizyonel hücreli karsinomunun (TCC) ilk tanı ve tedavisinde altın standart olmaya devam etmektedir. Ancak TUR'dan sonra hastaların %50-70'inde hastalık tekrarlar ve ilk tekrarın zamanı hastanın uzun vadeli prognozuyla ilişkilidir. Adjuvan intravezikal kemoterapi ve immünoterapi, ürologlar tarafından tümör nüksünü azaltmak, ilerlemeyi geciktirmek ve sağkalımı uzatmak amacıyla onlarca yıldır kullanılsa da, özellikle yüksek dereceli yüzeyel lezyonlarda eksik bir TUR, hasta sonuçlarını olumsuz etkileyecektir.
Referanslar
Slusarczyk, A., et al. The impact of smoking on recurrence and progression of non-muscle invasive bladder cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol, 2023. 149: 2673.
Miyake, M., et al. Active surveillance for nonmuscle invasive bladder cancer. Investig Clin Urol, 2016. 57 Suppl 1: S4.
Marcq, G., et al. Active surveillance for non-muscle invasive bladder cancer. Transl Androl Urol, 2019. 8: 54.
Tan, W.S., et al. International Bladder Cancer Group Intermediate-risk Nonmuscle-invasive Bladder Cancer Scoring System Predicts Outcomes of Patients on Active Surveillance. J Urol, 2023. 210: 763.
Aldousari S, Kassouf W. Update on the management of non-muscle invasive bladder cancer. Can Urol Assoc J. 2010 Feb;4(1):56-64.
Palou J, Sylvester RJ, Faba OR, et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. Eur Urol. 2012;62:118–125.
Marko Babjuk, Willem Oosterlinck, Richard Sylvester, Eero Kaasinen, Andreas Böhle, Juan Palou-Redorta, Morgan Rouprêt, EAU Guidelines on Non–Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update, European Urology, 2011;59(6): 997-1008.
Shariat SF, Palapattu GS, Amiel GE, et al. Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy. Urology. 2006;68(3):538–542.
Kobayashi S, Fujii Y, Koga F, et al. Impact of bladder neck involvement on progression in patients with primary non–muscle invasive bladder cancer: a prospective validation study. Urol Oncol. 2014;32(1):38.e29–38.e36.
Stein JP. Indications for early cystectomy. Urology. 2003;62:591–595.
Zhao C, Tang K, Yang H, et al. Bipolar versus monopolar transurethral resection of nonmuscle-invasive bladder cancer: a meta-analysis. J Endourol. 2016;30(1):5–12.
Kramer MW, Altieri V, Hrule R, et al. Current evidence of transurethral en-bloc resection of nonmuscle invasive bladder cancer. Eur Urol Focus.2017
Miladi M, Peyromaure M, Zerbib M. The value of a second transurethral resection in evaluating patients with bladder tumours. Eur Urol. 2003;43:241–245.
Vianello A, Costantini E, Del Zingaro M, et al. Repeated whitelight transurethral resection of the bladder in nonmuscleinvasive urothelial bladder cancers: systematic review and meta-analysis. J Endourol. 2011;25:1703–1712.
Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol. 2016;196(4):1021–1029.
Sfakianos JP, Kim PH, Hakimi AA, et al. The effect of restaging transurethral resection on recurrence and progression rates in patients with non–muscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin. J Urol. 2014;191:341–345.
Divrik RT, Sahin AF, Yildirim U, et al. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urotheilal carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomized clinical trial. Eur Urol. 2010;58:185–190.
Kramer MW, Altieri V, Hrule R, et al. Current evidence of transurethral en-bloc resection of nonmuscle invasive bladder cancer. Eur Urol Focus.2017.
Messing EM, Tangen C, Sahrasrabudhe DM, et al. A phase III blinded study of immediate post-TURBT instillation of gemcitabine vs saline in patients with newly diagnosed or occasionally recurring low grade non-muscle invading bladder cancer: SWOG S0337 (NCT 0045601). [Presented by Messing EM; May 15] 2017 [AUA 2017].
Barocas DA, Liu A, Burks FN, et al. Practice based collaboration to improve the use of immediate intravesical therapy after resection of nonmuscle invasive bladder cancer. J Urol. 013;190:2011–2016.
Shapiro O, Jones K, Wang C, et al. Risk of post-operative intravesical mitomycin C instillation following transurethral bladder tumor resection. Can J Urol. 2006;13(6):3317–3320.
Chou R, Selph S, Buckley DI, et al. Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis. J Urol. 2017;197:1189–1199.
Kurth K, Tunn U, Ay R, et al. Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of an EORTC randomized trial comparing doxorubicin, ethoglucid and TUR alone. J Urol. 1997;158:378–384.
Gan C, Amery S, Chatterton K, et al. Sequential bacillus Calmette-Guerin/electromotive drug administration of Mitomycin C as the standard intravesical regimen in high risk nonmuscle invasive bladder cancer: 2-year outcomes. J Urol. 2016;195:1697–1703.
Jung JH, Gudeloglu A, Kiziloz H, et al. Intravesical electromotive drug administration for non-muscle invasive bladder cancer. Cochrane Database Syst Rev. 2017;(9); 10.1002/14651858.CD011864 [CD011864].
Di Lorenzo G, Perdona S, Damiano R, et al. Gemcitabine versus Bacille Calmette-Guerin after initial bacilli Calmette-Guerin failure in non-muscle-invasive bladder cancer. Cancer. 2010;116:1893–1900.
Skinner EC, Goldman B, Sakr WA, et al. SWOG S0353: phase ii trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin. J Urol. 2013;190(4):1200–1204.
Breyer BN, Whitson JM, Carroll PR, et al. Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer. Urol Oncol. 2010;28:510–514.
Lightfoot AJ, Breyer BN, Rosevear HM, et al. Multiinstitutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer. Urol Oncol. 2014;32:35.e15–35.e19.
Steinberg RL, Thomas LJ, O'Donnell MA, et al. Sequential intravesical Gemcitabine and Docetaxel for salvage treatment of non-muscle invasive bladder cancer. Bladder Cancer. 2015;1:65–72.
Solsona E, Gonzalez M, Fernandez JM, et al. Random trial comparing intravesical chemo-induction with MMC to BCG vs. intravesical BCG in patients with intermediate-high risk superficial bladder cancer: efficacy evaluation of CUETO trial No 93008. Eur Urol. 2002;1(Suppl 1):101
Ehdaie B, Sylvester R, Herr HW. Maintenance bacillus Calmette-Guérin treatment of non–muscle-invasive bladder cancer: a critical evaluation of the evidence. Eur Urol. 2013;64(4):579–585.
Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013;63:462–472.
Morales A, Herr H, Steinberg G, et al. Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guérin. J Urol. 2015;193:1135–1143.
Steinberg RL, Nepple KG, Velaer KN, et al. Quadruple immunotherapy of Bacillus Calmette-Guérin, interferon, interleukin-2, and granulocyte-macrophage colonystimulating factor as salvage therapy for non-muscle-invasive bladder cancer. Urol Oncol. 2017;35:670.
Chamie K, Litwin MS, Bassett JC, Urologic Diseases in America Project, et al. Recurrence of high-risk bladder cancer: a population-based analysis. Cancer. 2013;119(17):3219–3227.
Tumors of the Bladder Max Kates MD, Trinity J. Bivalacqua MD, PhD. MD. Campbell-Walsh-Wein Urology. TWELFTH EDITION. Editor-in-Chief Alan W. Partin, MD, PhD .Elsevier. Philadelphia-CANADA. 2021:14116-14171.
Management Strategies for Non–Muscle-Invasive Bladder Cancer (Ta, T1, and CIS) Joseph Zabell MD, Badrinath R. Konety MD, MBAMD. Campbell-Walsh-Wein Urology. TWELFTH EDITION. Editor-in-Chief Alan W. Partin, MD, PhD .Elsevier. Philadelphia-CANADA. 2021:14193-14259.
Surgical Management of Bladder Cancer Transurethral, Open, and Robotic Neema Navai MD, Colin P.N. Dinney. MD. Campbell-Walsh-Wein Urology. TWELFTH EDITION. Editor-in-Chief Alan W. Partin, MD, PhD .Elsevier. Philadelphia-CANADA. 2021:14416-14493
